JAK1 Inhibitor Shows ‘Remarkable’ Activity in T-Cell Lymphoma
Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings from a single-arm phase II study showed. Among 88 heavily pretreated patients evaluable for efficacy, 44% (95% CI 34-55) responded to single-agent golidocitinib, with 24% (95% CI 15-34) achieving a […]
Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated promising efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to BTK inhibition, the phase I/II BRUIN study showed. Among 247 patients who had previously received a covalent BTK inhibitor, 73.3% (95% CI 67.3-78.7) achieved an overall […]
Post-Immunotherapy Combo Promising in Advanced RCC
Combination treatment with a hypoxia-inducible factor (HIF) 2α inhibitor and tyrosine kinase inhibitor induced responses in nearly a third of advanced renal cell carcinoma (RCC) patients previously treated with immunotherapy, a single-arm phase II study found. In the study of 52 patients, 30.8% (95% CI 18.7-45.1) had a confirmed objective response following treatment with belzutifan […]
Michael Wang on the Reversible BTK Inhibitor for Previously Treated MCL
The FDA recently granted accelerated approval to pirtobrutinib (Jaypirca), a reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a BTK inhibitor. In this exclusive MedPage Today video, Michael Wang, MD, of the University of Texas MD […]
Novel BTK Inhibitor Looks Good for Sjogren’s Syndrome
PHILADELPHIA — Remibrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, appeared effective in reducing signs of Sjogren’s syndrome in a randomized, placebo-controlled trial. Scores on the EULAR Sjogren’s Syndrome Activity Index (ESSDAI), a comprehensive measure of Sjogren’s severity, fell by 2.86 points with the oral drug relative to placebo during the 24-week trial, according to […]
Triplet in First-Line Kidney Cancer Thwarts Disease Progression
PARIS — Adding the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) to dual immune checkpoint inhibition improved progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), the phase III COSMIC-313 trial found. Among 550 patients with untreated intermediate- or poor-risk disease, those treated with the triplet therapy had a median PFS that was not […]
First TYK2 Inhibitor for Psoriasis Wins FDA Approval
The FDA approved the first-in-class oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis, Bristol Myers Squibb announced. The indication limits use to adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is not recommended for use with other immunosuppressant drugs. “Sotyktu has the potential to become the new standard-of-care oral […]
Erdafitinib Continues to Show Efficacy in Urothelial Carcinoma
The pan-FGFR tyrosine kinase inhibitor erdafitinib (Balversa) was active and safe in patients with locally advanced or metastatic urothelial carcinoma, according to long-term follow-up of a phase II study. At a median follow-up of 24 months, the investigator-assessed objective response rate (ORR) was 40% among 101 patients with prespecified FGFR alterations treated with erdafitinib, reported […]
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor led to better oncologic outcomes compared with ibrutinib (Imbruvica) for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), according to an interim analysis of the phase III ALPINE study. Over a median follow-up of 15 months, the overall response rate — the primary […]
Brepocitinib Shows Promise in Phase II Trial for PsA
The oral tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib showed efficacy for psoriatic arthritis (PsA) in a phase IIb trial. At week 16, a 20% improvement on the criteria of the American College of Rheumatology (ACR20) was observed in 66.7% of patients receiving 30 mg brepocitinib daily as did 74.6% of those given 60 mg […]